Concurrently, the Company is expanding the previously announced canine study to include refined samples and a direct challenge model that pits the company's bioactive compounds against glucosamine and chondroitin – the most popular active ingredients in the canine joint health supplement market.
"Glucosamine and chondroitin are the most common supplement ingredients available to consumers for pet health. The market is large and stable, even in the current economic climate," states Dahl. "We'd like to offer dog owners a viable alternative that can be more cost-effectively and safely administered for months, if not years, without any worries and also provide the additional benefit of a healthy immune system response."
Like their human owners, dogs and other animals serving as family pets and companions in the USA and around the world experience loss of joint health due to advancing age, weight, and breed type. Joint health issues are predicted to affect nearly 1 in 5 dogs, and the canine joint health supplement market currently generates roughly $300 million in annual sales in the U.S. alone.
Results from the glucosamine-chondroitin challenge experiment are expected in mid-to-late September, at which point Company principals hope to be in a position enter discussions with potential joint-venture partners and licensees to position specific product applications for market introduction.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCQB: HEPI) is a Michigan-based biotech company engaged in the investigation of the health benefits of bioactive compounds derived from its proprietary algal
|SOURCE Health Enhancement Products, Inc.|
Copyright©2014 PR Newswire.
All rights reserved